DISCLAIMER
The assessment tools contained in this Application ("Assessment Tools") are intended only to
be an informational tool for clinicians who have been allowed access to the Application by
BI. The Assessment Tools are not intended to provide general or specific medical advice. The
Assessment Tools do not take into account other considerations including, but not limited
to, drug interactions, contraindications and patient history, and other risk factors.
Therefore, the Application and Assessment Tools should be used as a general guide only and
any specific advice provided by clinicians should be based on a professional review and
consideration of each patient.
In cases of emergency surgery or urgent procedures
1:
•
When the rapid reversal of the anticoagulant effect of Pradaxa is required (for patients
who required that can not be delayed for at least 8 hours and for which normal
haemostatis is desirable)2, the specific reversal agent
(PRAXBIND®, idarucizumab) to PRADAXA® is
available.1
Depending on the clinical condition of the patient, coagulation testing can be of value to
determine the presence or absence of circulating dabigatran.2
The aPTT test may be useful in determining an excess of anticoagulant activity. Dabigatran
concentration exceeding 450-500 ng/mL would result in an aPTT of greater than 2.5 times control.
An aPTT greater than 2.5 times control is suggestive of excess anticoagulation.
The TT test can determine the presnse or absence of dabigatran in the circulation and, together
with an aPTT, may also be useful.2
1. PRAXBIND Approved Product Information, 14 January 2022.
2. Eikelboom J et al. Idarucizumab. The Antidote for Reversal of Dabigatran, Circulation.
2015;132:2412-2422